Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company specializing in the development of novel radiotherapy enhancers for oncology applications. Founded in 2003 and headquartered in Paris, France, Nanobiotix’s primary focus is on improving the precision and efficacy of existing radiotherapy treatments. The company’s proprietary technology platform leverages inorganic nanoparticles designed to increase the local dose of radiation absorbed by tumors, potentially enhancing tumor control while sparing surrounding healthy tissue.

The company’s flagship product candidate, NBTXR3, is a first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles. Administered via a single intratumoral injection prior to standard radiotherapy, NBTXR3 has been studied across several solid tumors, including soft tissue sarcoma, head and neck cancer, prostate cancer and liver metastases. Nanobiotix continues to advance its clinical pipeline through Phase II and Phase III trials, exploring both monotherapy applications and combination regimens with chemotherapy and immuno-oncology agents.

Nanobiotix maintains a global footprint, with offices and research facilities in Europe and the United States. The company’s European headquarters and primary R&D center are located in Paris and Lyon, France, while its U.S. operations are based in New York City and Cambridge, Massachusetts. This transatlantic presence supports collaborative partnerships with leading academic institutions, as well as strategic alliances with pharmaceutical companies to expedite clinical development and regulatory approvals.

Under the leadership of Co‐Founder and Chief Executive Officer Dr. Laurent Levy, Nanobiotix is guided by a management team with extensive experience in oncology drug development, medical device innovation and commercial operations. The company’s board of directors and scientific advisory committee comprise seasoned experts in radiobiology, nanotechnology and clinical oncology. With a commitment to advancing treatment options for cancer patients, Nanobiotix continues to expand its pipeline and seek regulatory clearances across key global markets.

Key Stats

• Today's Range: $5.23 to $5.50
• 50-Day Range: $3.31 to $5.76
• 52-Week Range: $2.76 to $6.00
• Volume: 3,490 shs
• Average Volume: 15,420 shs
• Market Capitalization: $250.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 45% of companies evaluated by MarketBeat, and ranked 722nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Nanobiotix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 66.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 66.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.31

News Sentiment

Nanobiotix has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nanobiotix this week, compared to 1 article on an average week.

Search Interest

1 people have searched for NBTX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

Only 38.81% of the stock of Nanobiotix is held by institutions.

NBTX Stock Analysis - Frequently Asked Questions

How have NBTX shares performed this year?

Nanobiotix's stock was trading at $2.87 on January 1st, 2025. Since then, NBTX shares have increased by 89.5% and is now trading at $5.44.

When did Nanobiotix IPO?

Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

How do I buy shares of Nanobiotix?

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nanobiotix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG).

Company Calendar

• Today: 7/10/2025
• Next Earnings (Estimated): 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NBTX
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nanobiotix: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +49.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.04
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: -$11.61 million
• Price / Sales: -21.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.51) per share
• Price / Book: -3.54

Miscellaneous

• Outstanding Shares: 47,133,000
• Free Float: 45,507,000
• Market Cap: $251.69 million
• Optionable: Not Optionable
• Beta: 0.41